Source - LSE Regulatory
RNS Number : 3681P
Deltex Medical Group PLC
31 August 2017
 

31 August 2017

 

 

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

 

 

Notice of Interim Results

 

 

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), will be announcing its Interim Results for the six months ended 30 June 2017, on Monday 11 September 2017.

Management will be hosting a presentation for analysts on the day of results at 11:00am the offices of Arden Partners plc, 125 Old Broad Street, London, EC2N 1AR.

Analysts who wish to attend should register their interest with Heather Armstrong contactable at heather.armstrong@investor-focus.co.uk or 0203 053 8671.

 

For further information, please contact:-

 

Deltex Medical Group plc                               

01243 774 837

investorinfo@deltexmedical.com

Nigel Keen, Chairman                        


Ewan Phillips, Chief Executive          


Jonathan Shaw, Group Finance Director




Nominated Adviser & Broker


Arden Partners plc

020 7614 5900

Chris Hardie

Ciaran Walsh


 

Turner Pope Investments (TPI) Ltd

 

0203 621 4120

jess@turnerpope.com

Ben Turner

James Pope


 

Financial Public Relations


IFC Advisory

0203 053 8671

Tim Metcalfe

Graham Herring

Heather Armstrong


 

 

Notes for Editors

 

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

 

Deltex Medical's CardioQ-ODM+ platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

 

Company goal

 

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Company aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition and skill and expertise of the user. Doing this will enable the Company to partner healthcare providers to support modern haemodynamic management across the whole hospital.

 

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

 

There are over 3,400 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable products.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORSDSESSFWSELA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.